The Brigham and Dana-Farber Board Review in Hematology 2020 (Videos+PDFs)

The Brigham and Dana-Farber Board Review in Hematology 2020

Brigham and Women’s Hospital Board Review

Product Details

Stay Current with this In-Depth Review

The Brigham and Dana-Farber Board Review in Hematology online CME program brings together a distinguished group of experts to present current diagnostic and therapeutic strategies. Enhance patient care and prepare for boards with topics like molecular genetics, leukemia, bone marrow failures, transfusion medicine and more. You will learn to:

• Apply current/recommended hematology guidelines in clinical practice
• Perform differential diagnosis of complex hematologic disorders
• Identify and apply current therapeutic options for hematologic disorders
• Evaluate and interpret up-to-date literature relevant to clinical practice in hematology
• Illustrate knowledge of pathophysiology of hematology disorders
• Apply knowledge gained to the ABIM certification/recertification

Discover New Guidelines

A clinically based update, this learn-at-your-own-pace CME course in hematology provides a maximum of 25.25 AMA PRA Category 1 Credits ™ and 25.25 MOC points. Available online or via USB, it provides access to unbiased, evidence-based content and case-based reviews so you can expand your knowledge and incorporate the latest guidelines into your daily practice.

Accreditation

Oakstone Publishing is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

Oakstone Publishing designates this enduring material for a maximum of 25.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn 25.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Date of Original Release: April 15, 2020

Termination Date: April 15, 2023

Learning Objectives

At the conclusion of this activity, the participant will be able to:

• Apply current/recommended Hematology guidelines in clinical practice
• Perform differential diagnosis of complex clinical presentations related to Hematologic disorders
• Identify/apply current therapeutic options for specific Hematologic disorders
• Review and interpret up-to-date literature relevant to clinical practice in Hematology
• Demonstrate knowledge of pathophysiology as it applies to management of Hematology disorders
• Apply knowledge gained to the ABIM Certification/Recertification Hematology and Oncology examinations

Intended Audience

The activity was planned for fellows/trainees, practicing Hematology specialists (MDs), and other professional affiliates (internists with an interest in Hematology) who are preparing to take ABIM Board Review or Recertification Examinations, or who seek CME activities to improve patient care in the areas of Hematology Medicine.

Topics/Speaker:

• Molecular Genetics of Cancer – Nikhil Wagle, MD

• Advances in Cancer Drug Development – Geoffrey I. Shapiro, MD, PhD

• Infections in Cancer Patients – Lindsey Baden, MD

• Symptom Management in Patients with Cancer – Andrew J. Lawton, MD

• Communication: The Key to Excellence in End-of-Life Care – Rachelle E. Bernacki, MD

• Biology of Hematopoietic Stem Cell Transplantation – Robert J. Soiffer, MD

• Biology of Acute Leukemia and Myelodysplastic Syndromes – Benjamin L. Ebert, MD, PhD

• Acute Leukemias – Daniel J. DeAngelo, MD, PhD

• Myelodysplastic Syndrome – David P. Steensma, MD

• Chronic Myelogenous Leukemia – Marlise R. Luskin, MD

• Myeloproliferative Syndromes – Ann M. Mullally, MD

• Multiple Myeloma – Kenneth C. Anderson, MD

• Waldenstrom Macroglobulemia and Amyloidosis – Jorge Castillo , MD

• Low Grade Lymphomas – Caron A. Jacobson, MD

• High Grade Lymphomas – Eric D. Jacobsen, MD

• Hodgkin’s Lymphoma – Jennifer Crombie, MD

• Diagnosis and Treatment of CLL and Related B Cell Malignancies – Matthew S. Davids, MD

• Hematopoiesis and Cytokines – David T. Scadden, MD

• Acquired Bone Marrow Failure – Julie-Aurore Losman, MD, PhD

• Congenital Bone Marrow Failure – Akiko Shimamura, MD, PhD

• Hemophagocytic Syndromes and Related Immunodeficiencies – Barbara A. Degar, MD

• Anemia: An Overview – Ronald P. McCaffrey, MD

• Iron Deficiency and Iron Overload – Mark D. Fleming, MD, PhD

• Immune Hemolytic Anemia – Richard M. Kaufman, MD

• Non-immune Hemolytic Anemia – David E. Golan, PhD, MD

• Sickle Cell Disease – Maureen M. Achebe, MD, MPH

• Thalassemia and Other Hemoglobinopathies – Matthew M. Heeney, MD

• Disorders of Neutrophils – Nancy Berliner, MD

• Acquired Thrombocytopenias – Elisabeth M. Battinelli, MD, PhD

• Hemophilia – Aric D.Parnes, MD

• Von Willebrand Disease and Congenital Platelet Disorders – Nathan T. Connell, MD, MPH

• Congenital and Acquired Thrombophilia – Kenneth A. Bauer, MD

• Use of Direct Oral Anticoagulants in Clinical Practice – Jean M. Connors, MD

• Transfusion Medicine for the Clinician – Walter H. Dzik, MD